Young Investigator Meeting (YIM)
Meeting date is May 12, 2017!
One of the goals of the iwCLL is to promote the development of emerging scientists, both clinic- and laboratory-based, who will continue to unravel unanswered questions in CLL. Since 2005, iwCLL has been preceded by a Young Investigator Meeting (YIM), which offers an opportunity for investigators less than 40 years of age to present and discuss their data.
The YIM is a forum for tomorrow’s leaders to network and collaborate with today’s CLL experts. Because of its relaxed atmosphere that facilitates interaction between emerging and established leaders in CLL, the YIM has fostered growth of the field and spurred new research and collaboration.
The purpose of the YIM is to facilitate the professional development of young basic and clinical scientists in the field of CLL research. By providing an opportunity for young investigators to share their research interest in CLL, the YIM planners hope to promote their participation in the iwCLL and encourage their interaction with established senior CLL scientists and investigators to help advance their careers.
–Shih-Shih Chen, MD; 2017 YIM Planning Committee
The YIM is planned as a relaxed forum in which junior researchers—the people normally conducting much of the CLL research under the direction of more senior scientists and clinicians—can discuss their own data and solicit feedback from peers, mentors, and experts.
The full-day YIM preceding the iwCLL will present exciting new concepts emerging from clinic- and laboratory-based research regarding the pathobiology and treatment of CLL, still an incurable disease despite numerous recent breakthroughs. The 2017 YIM will be organized around the following themes, which mirror those of iwCLL:
• Emerging evidence regarding factors that contribute to the development of CLL
• Emerging evidence regarding the diagnosis, prognosis, and initial treatment of CLL
• Emerging evidence regarding factors that contribute to disease evolution and progression
• Emerging evidence regarding therapy for advanced disease
The YIM is a forum to share critical updates while providing participants an opportunity to make important connections,
gain insight into the latest treatment strategies, and leave inspired to advance the care for patients with CLL.
The majority of the content for the YIM will be derived from selected abstracts. The planners expect the quality of the abstracts to be extremely high, as in past years. In addition, Arnon Kater, MD, PhD (Lymphoma and Myeloma Center, University of Amsterdam, the Netherlands) will discuss pursuing a career in CLL research. A final agenda and faculty list are anticipated in March 2017.
After participating in the YIM, participants should be better able to evaluate and interpret the clinical significance of emerging evidence regarding:
• Factors that contribute to the development of CLL
• The diagnosis, prognosis, and initial treatment of CLL
• Factors that contribute to disease evolution and progression treatment of advanced disease
• Treatment of advanced disease
YIM Committee gratefully acknowledges the CLL Global Research Foundation for their generous support and sponsorship of the YIM travel grants